文献速递免疫规划传染病防控与疫情报告

改进流感病毒H7N9重组血凝素免疫原性用于疫苗研发

Improving immunogenicity of influenza virus H7N9 recombinant hemagglutinin for vaccine development.
PubMed 文献 · Vaccine · 2019-01-01

本研究利用杆状病毒系统表达两种H7血凝素构建体:膜结合全长HA(mH7)和分泌型胞外域H7(sH7),评估其稳定性与免疫原性。mH7可形成寡聚体-玫瑰花结结构且HA滴度高,而sH7不能形成该结构且交联前无HA滴度。小鼠免疫研究中仅mH7能诱导稳健的HI和中和抗体滴度,提示mH7候选疫苗值得进一步开发。

要点

  • mH7构建体可形成寡聚体-玫瑰花结结构,HA滴度为8192。
  • sH7构建体不能形成寡聚体-玫瑰花结结构,交联前无HA滴度。
  • 小鼠免疫中仅mH7诱导稳健的HI和中和抗体滴度。

核心结论

  • mH7构建体可诱导稳健的HI和中和抗体滴度,值得进一步开发为H7N9疫苗候选。

研究设计与样本

  • 利用杆状病毒系统表达两种H7 HA构建体(mH7和sH7),评估稳定性与免疫原性。
  • 小鼠免疫研究评估两种构建体诱导的HI和中和抗体滴度。

主要发现

  • mH7可形成寡聚体-玫瑰花结结构,HA滴度为8192。
  • sH7不能形成寡聚体-玫瑰花结结构,交联前无HA滴度。
  • sH7和mH7分别在43°C和52°C下不稳定。
  • 小鼠免疫中mH7而非sH7能诱导稳健的HI和中和抗体滴度。

临床怎么用

  • 优先推进mH7构建体作为H7N9疫苗候选的进一步开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Human infections of novel avian influenza A virus (H7N9) emerged in early 2013 and caused about 40% case-fatality through 2017. Therefore, development of influenza H7N9 vaccines is critical for pandemic preparedness. Currently, there are three means of production of commercial influenza vaccines: egg-based, mammalian cell-based, and insect cell-based platforms. The insect cell-based platform has the advantage of high speed in producing recombinant protein. In this study, we evaluate the stability and immunogenicity of two different influenza H7 HA expression constructs generated using the baculovirus system, including membrane-based full-length HA (mH7) and secreted ectodomain-based H7 (sH7). The mH7 construct could form an oligomer-rosette structure and had a high hemagglutinin (HA) titer 8192. In contrast to mH7, the sH7 construct could not form an oligomer-rosette structure and did not have HA titer before cross-linking with anti-His antibody. Thermal stability tests showed that the sH7 and mH7 constructs were unstable at 43 °C and 52 °C, respectively. In a mice immunization study, the mH7 construct but not the sH7 construct could induce robust HI and neutralizing antibody titers. In conclusion, further development of the mH7 vaccine candidate is desirable.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ting-Hui-Lin, Chia MY, Lin CY, et al. Improving immunogenicity of influenza virus H7N9 recombinant hemagglutinin for vaccine development. Vaccine. 2019. PMID: 30857635. doi:10.1016/j.vaccine.2018.09.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。